#Merck

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

United States of America map with state names

$7M HIV Initiative to Help Underserved People in the Southeast

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

$7M HIV Initiative to Help Underserved People in the Southeast

Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen

A mid-stage trial showed the combo suppressed HIV, was well tolerated and resulted in a low rate of virologic failure.

Overcoming the Persistence of Stigma

Youth activists living with HIV are speaking truth to power.

What Do Gen Z and Millennials Think About HIV?

A new survey and educational campaign called “Owning HIV” offer insight.

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

Islatravir Shows Double Potential

Merck’s experimental HIV drug proves effective and well tolerated

Pifeltro

The International AIDS Society Conference’s Most Vital Findings

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Merck’s Experimental HIV Drug Islatravir Proves Effective and Well Tolerated

This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.

Long-Lasting Islatravir PrEP Implant Could Protect Against HIV for a Year

Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.

Pharma CEOs Walk Into a Congressional Hearing to Defend High Drug Prices…

Stop me if you’ve heard this one before.

Merck Files With FDA for Expanded Approval of Pifeltro and Delstrigo

An OK would add an indication for the use of these HIV medications among those switching from stable regimens.

2018 Top HIV Treatment Stories

Here are the HIV treatment news stories with the most views this year.

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Switching to Merck’s New HIV Regimen Delstrigo Is Safe and Effective

According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.

Picking Up the Pieces

The Impact of Hurricane Maria on HIV

Treatment: Merck’s Doravirine

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

#Merck

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

$7M HIV Initiative to Help Underserved People in the Southeast

Very Low-Dose Weekly Islatravir Works as PrEP in Monkeys

FDA OKs Delstrigo and Pifeltro

$7M HIV Initiative to Help Underserved People in the Southeast

Islatravir Plus Pifeltro Shows Promise as 2-Drug HIV Regimen

Overcoming the Persistence of Stigma

What Do Gen Z and Millennials Think About HIV?

Switching to New Tenofovir Linked to Rise in BMI and Cardiovascular Risk

Islatravir Shows Double Potential

Pifeltro

The International AIDS Society Conference’s Most Vital Findings

Merck’s Experimental HIV Drug Islatravir Proves Effective and Well Tolerated

Long-Lasting Islatravir PrEP Implant Could Protect Against HIV for a Year

Pharma CEOs Walk Into a Congressional Hearing to Defend High Drug Prices…

Merck Files With FDA for Expanded Approval of Pifeltro and Delstrigo

2018 Top HIV Treatment Stories

Older Tenofovir May Not Be Tied to Fracture Risk After All

Switching to Merck’s New HIV Regimen Delstrigo Is Safe and Effective

Picking Up the Pieces

Treatment: Merck’s Doravirine

Treatment News

Features